Just days ago, MD Anderson researcher Jennifer Wargo and colleagues published new research that showed how the gut microbiome played a big role in determining whether or not a checkpoint therapy could help save your life. This morning, MD Anderson and the scientific network aficionados at the Parker Institute have put a deal together to collaborate with leading micriobiome biotech Seres on a pill. Seres’ $MCRB bacteria pill is the preclinical SER-401. And the biotech landed a deal for MD Anderson’s IP. The Parker Institute will sponsor a clinical trial to see if it works.
You Might Also Like...
Targeted Therapy, Vaccines, CAR-T, and a Practice Changer at AACR 2019
OBR | April 24, 2019